Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Duke University Medical Center, Durham, NC, United States

Survival: 11.9 months
Toxicity Grade: 3
Treatments: Biologic therapy
Drugs: Gliadel Wafer
Country: United States
City/State/Province: Durham, NC
Hospital: Duke University Medical Center
Journal: Link
Date: 2/2009

This phase 2 trial involved 52 patients with recurrent glioblastoma multiforme, 30 males and 22 females. Patient age ranged from 25 to 69, with a median of 51.5.

Patients were given a chemotherapeutic drug, Gliadel (generic name carmustine), which blocks DNA replication and growth of cancer cells. Wafers of this drug were implanted at the tumor site during surgery. In addition, a biologic agent called O6-benzylguanine was administered after surgery. This drug blocks a DNA repair protein in cells that might be involved in tumor resistance to drugs like Gliadel.

The highest toxicity level observed in patients was Grade 3, most commonly in the form of brain or cerebrospinal fluid leak (in 19.2% of patients) or infection (in 13.4%). Hydrocephalus, also known as “water on the brain”, was also observed in 9.6% of patients.

The median overall survival in this study was 11.9 months.

This study was funded in part by MGI Pharma, the makers of the Gliadel drug.

Correspondence: Dr. Henry Friedman

E-mail to a Friend Email Physician More Information